Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 8—August 2021
Dispatch

SARS-CoV-2 Prevalence among Outpatients during Community Transmission, Zambia, July 2020

Jonas Z. HinesComments to Author , Sombo Fwoloshi, Davies Kampamba, Danielle T. Barradas, Dabwitso Banda, James E. Zulu, Adam Wolkon, Samuel Yingst, Mary Adetinuke Boyd, Mpanji Siwingwa, Lameck Chirwa, Muzala Kapina, Nyambe Sinyange, Victor Mukonka, Kennedy Malama, Lloyd B. Mulenga, and Simon Agolory
Author affiliations: US Centers for Disease Control and Prevention, Lusaka, Zambia (J.Z. Hines, D.T. Barradas, A. Wolkon, S. Yingst, M.A. Boyd, S. Agolory); University Teaching Hospital, Lusaka (S. Fwoloshi, D. Kampamba, M. Siwingwa, L. Chirwa, L.B. Mulenga); Zambia Ministry of Health, Lusaka (S. Fwoloshi, K. Malama, L.B. Mulenga); Zambia Field Epidemiology Training Program, Lusaka (D. Banda, J.E. Zulu); Zambia National Public Health Institute, Lusaka (M. Kapina, N. Sinyange, V. Mukonka)

Cite This Article

Abstract

During the July 2020 first wave of severe acute respiratory syndrome coronavirus 2 in Zambia, PCR-measured prevalence was 13.4% among outpatients at health facilities, an absolute difference of 5.7% compared with prevalence among community members. This finding suggests that facility testing might be an effective strategy during high community transmission.

The first cases of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease (COVID-19), were reported in Zambia in March 2020 (1). During the first wave of infections, confirmed cases rapidly increased during July and peaked in August 2020 (Appendix). Zambia initially focused on screening travelers at points-of-entry and tracing contacts of persons with laboratory-confirmed cases. In April 2020, the Zambia Ministry of Health began SARS-CoV-2 surveillance among hospital inpatients and outpatients to identify cases of local transmission (1,2). It was believed that testing in health facilities would be more efficient at identifying cases than testing in the general population, which was particularly noteworthy given the severe shortage of SARS-CoV-2 tests in Africa early in the pandemic (3,4). A household prevalence survey conducted in 6 districts in Zambia in July 2020 found a community SARS-CoV-2 prevalence of 7.6% by using real-time PCR (rPCR) (5). To determine if facility testing was an effective case-finding strategy during a period of high community transmission, we compared SARS-CoV-2 prevalence among outpatients, overall and stratified by reasons for visiting the facility, with prevalence among community members in the same districts (5).

The Study

During July 2–31, 2020, we administered a cross-sectional prevalence survey of patients attending 20 outpatient clinics, including hospitals and health centers, in 6 districts in Zambia (Appendix). The number of facilities we selected in each district was proportional to the number of facilities in the other districts (Appendix). We recruited participants from outpatient departments regardless of their reason for visiting the facilities. Study teams were instructed to recruit ≥50 participants per facility and to attempt to show no preference in selection. We obtained consent or assent (for minors) before beginning study procedures. Participants completed an interviewer-administered questionnaire that included demographics, medical history, SARS-CoV-2 exposures, history of recent illness, and reason for visiting the facility. Concurrently, we conducted a cluster-sampled household prevalence survey in the same 6 districts (5). These surveys provided an opportunity to directly compare outpatient and community SARS-CoV-2 prevalence estimates. The study was approved by the Zambia National Health Research Authority and the University of Zambia Biomedical Research Ethics Committee. The activity was reviewed by the US Centers for Disease Control and Prevention (CDC) and conducted consistent with applicable US federal law and CDC policy.

We tested nasopharyngeal specimens for SARS-CoV-2 RNA by using rPCR and plasma specimens for SARS-CoV-2 antibodies by using ELISA. We extracted RNA for rPCR using the QIAGEN Viral Mini procedure (https://www.qiagen.com). We used the Maccura SARS-CoV-2 Fluorescent PCR kit (https://www.maccura.com) on the QuantStudio 3 platform (ThermoFisher, https://www.thermofisher.com) as the primary rPCR diagnostic (6) and used the CDC assay method to confirm positive and indeterminant results (7). We performed the Euroimmun ELISA (PerkinElmer, https://www.perkinelmer.com) to test for spike protein IgG in single replicate (8). Participants could take part in any or all of the survey, rPCR testing, or serologic testing options based on personal preference.

We calculated SARS-CoV-2 prevalence as the number of positive results divided by the total number of tests conducted. Estimates were calculated separately for rPCR and ELISA results. We adjusted variance and 95% CIs for clustering by facility and seroprevalence for imperfect assay test characteristics (sensitivity 64.2%; specificity 100%; L. Steinhardt, pers. comm., email, 2021 Apr 2) using the Rogan-Gladen method (Appendix). To assess various factors associated with SARS-CoV-2 prevalence among outpatients, we used bivariate Poisson regression models to calculate prevalence ratios (PRs) and 95% CIs, with a random effects term for facility.

Of 1,975 persons representing ≈3.5% of ≈57,000 outpatients from the 20 facilities that we approached in July 2020 about participating (District Health Information System version 2; https://dhis2.org), 1,952 (98.8%) completed the questionnaire and 1,908 (97.7%) submitted either nasopharyngeal (1,490; 76.3%) or blood (1,657; 84.3%) specimens or both (Appendix). Of the 1,952 total participants, the number per district ranged from 160 (8.2%) in Nakonde District to 639 (32.8%) in Lusaka District; the median number of participants per facility was 93 (interquartile range 78–107; Table 1). Median participant age was 32 years (interquartile range 24–43 years); 60.5% were female. Overall, 34.1% of participants reported having a coexisting medical condition. Fever or respiratory complaints accounted for 28.2% of reasons for visiting the facility; 2.3% of participants were specifically seeking COVID-19 testing.

SARS-CoV-2 rPCR-measured prevalence was 13.4% (95% CI 8.3%–18.5%; Table 1); SARS-CoV-2 ELISA-measured prevalence was 8.2% (95% CI 5.1%–11.4%). Compared with community members, outpatients overall had higher rPCR-measured prevalence (PR 1.8, 95% CI 1.1–2.9; Table 2) as did those seeking COVID-19 testing (PR 3.6, 95% CI 2.2–5.9) or those without a stated reason for the visit (PR 2.0, 95% CI 1.2–3.3). Although only 2.2% of participants reported contact with confirmed COVID-19 case-patients, rPCR-measured prevalence was higher among outpatients specifically seeking COVID-19 testing compared with outpatients attending facilities for another reason (PR 2.2, 95% CI 1.4–3.3). In addition, outpatients had higher ELISA-measured prevalence than community members (PR 2.5, 95% CI 1.4–4.5) (Appendix). Among outpatients with SARS-CoV-2 infection, 45.7% did not report experiencing any symptoms associated with SARS-CoV-2.

Conclusions

Outpatients had higher SARS-CoV-2 prevalence than did community members in Zambia. Given the high SARS-CoV-2 prevalence and proportion of asymptomatic infections among outpatients, without instituting protective measures facilities might become transmission foci. Ameliorating risk requires instituting robust prevention and control strategies including universal masking in facilities (9,10). Furthermore, persons seeking testing at facilities should be quickly identified and isolated, because they might be at particularly high risk for having the virus.

One limitation of our study is that underlying condition and exposure history are subject to self-report and recall biases. The districts and facilities were not randomly selected and, despite our intentions to remain unbiased, may not have been representative of the population. The small sample size may have affected our ability to detect differences in factors associated with SARS-CoV-2 prevalence. The higher ELISA-measured prevalence among outpatients than community members could signal noncomparability between these 2 populations or that being an outpatient is a possible marker for other behaviors that increase SARS-CoV-2 infection risk. We assumed exact sensitivity and specificity values for the serology assay, but emerging evidence on serologic cross-reactivity (1113) and antibody decay (14) might affect these values. However, given the timing of our study early in the outbreak, antibody decay was unlikely to substantially affect sensitivity (J. Perez-Saez, unpub. data, https://doi.org/10.1101/2021.03.16.21253710).

Countries with limited testing capacity need efficient strategies to identify persons with SARS-CoV-2 infections to interrupt transmission. In Zambia, when measured by rPCR, outpatients had 80% higher SARS-CoV-2 prevalence than persons in the surrounding community. Testing all outpatients regardless of their reasons for visiting the facility during periods of community transmission might help identify otherwise undetected SARS-CoV-2 infections. Compared with community-based SARS-CoV-2 testing, outpatient testing, which is often more convenient, might identify cases more effectively. Therefore, testing at facilities during periods of high community transmission might be an effective strategy to identify persons with SARS-CoV-2 infection, especially when testing capacity is limited.

Dr. Hines is the surveillance advisor in the US Centers for Disease Control and Prevention Center for Global Health field office in Lusaka, Zambia. He is an internal medicine physician with 6 years of international public health experience, including in areas of surveillance methodology and public health workforce capacity building.

Top

Acknowledgment

This work has been supported by the President’s Emergency Plan for AIDS Relief through the Centers for Disease Control and Prevention and its emergency response to the COVID-19 pandemic.

Top

References

  1. Chipimo  PJ, Barradas  DT, Kayeyi  N, Zulu  PM, Muzala  K, Mazaba  ML, et al. First 100 Persons with COVID-19 - Zambia, March 18-April 28, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:15478. DOIPubMedGoogle Scholar
  2. Zambia Ministry of Health. Implementation strategy—active screening for COVID-19 in health facilities. Lusaka (ZM): Zambia Ministry of Health; 2020.
  3. Nkengasong  J. Let Africa into the market for COVID-19 diagnostics. Nature. 2020;580:565. DOIPubMedGoogle Scholar
  4. Kavanagh  MM, Erondu  NA, Tomori  O, Dzau  VJ, Okiro  EA, Maleche  A, et al. Access to lifesaving medical resources for African countries: COVID-19 testing and response, ethics, and politics. Lancet. 2020;395:17358. DOIPubMedGoogle Scholar
  5. Mulenga  LB, Hines  JZ, Fwoloshi  S, Chirwa  L, Siwingwa  M, Yingst  S, et al. Prevalence of SARS-CoV-2 in six districts in Zambia in July, 2020: a cross-sectional cluster sample survey. Lancet Glob Health. 2021;9:e77381. DOIPubMedGoogle Scholar
  6. Maccura Biotechnology. SARS-CoV-2 fluorescent PCR kit: instructions for use. 2020 [cited 27 May 2021]. https://www.fda.gov/media/137026/download
  7. Centers for Disease Control and Prevention. CDC 2019-novel coronavirus (2019-nCoV) real-time RT-PCR diagnostic panel. 2020 [cited 27 May 2021] https://www.fda.gov/media/134922/download
  8. U.S. Food and Drug Administration. Serology test evaluation report for “SARS-COV-2 ELISA (IgG)” from Euroimmun. 2020 [cited 27 May 2021] https://www.accessdata.fda.gov/cdrh_docs/presentations/maf/maf3246-a001.pdf
  9. Wang  X, Ferro  EG, Zhou  G, Hashimoto  D, Bhatt  DL. Association between universal masking in a health care system and SARS-CoV-2 positivity among health care workers. JAMA. 2020;324:7034. DOIPubMedGoogle Scholar
  10. Kim  H, Hegde  S, LaFiura  C, Raghavan  M, Sun  N, Cheng  S, et al. Access to personal protective equipment in exposed healthcare workers and COVID-19 illness, severity, symptoms and duration: a population-based case-control study in six countries. BMJ Glob Health. 2021;6:e004611. DOIPubMedGoogle Scholar
  11. Tso  FY, Lidenge  SJ, Peña  PB, Clegg  AA, Ngowi  JR, Mwaiselage  J, et al. High prevalence of pre-existing serological cross-reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in sub-Saharan Africa. Int J Infect Dis. 2021;102:57783. DOIPubMedGoogle Scholar
  12. Nkuba Ndaye  A, Hoxha  A, Madinga  J, Mariën  J, Peeters  M, Leendertz  FH, et al. Challenges in interpreting SARS-CoV-2 serological results in African countries. Lancet Glob Health. 2021;9:e5889. DOIPubMedGoogle Scholar
  13. Steinhardt  LC, Ige  F, Iriemenam  NC, Greby  SM, Hamada  Y, Uwandu  M, et al. Cross-reactivity of two SARS-CoV-2 serological assays in a malaria-endemic setting. J Clin Microbiol. 2021; [Epub ahead of print]. DOIGoogle Scholar
  14. Choe  PG, Kim  K-H, Kang  CK, Suh  HJ, Kang  E, Lee  SY, et al. Antibody responses 8 months after asymptomatic or mild SARS-CoV-2 infection. Emerg Infect Dis. 2021;27:92831. DOIPubMedGoogle Scholar

Top

Tables

Top

Cite This Article

DOI: 10.3201/eid2708.210502

Original Publication Date: June 29, 2021

Table of Contents – Volume 27, Number 8—August 2021

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Jonas Z. Hines, CDC–Zambia Office, PO Box 320065, 351 Independence Way, Woodlands, Lusaka, Zambia

Send To

10000 character(s) remaining.

Top

Page created: May 14, 2021
Page updated: July 18, 2021
Page reviewed: July 18, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external